GLSI — Greenwich Lifesciences Cashflow Statement
0.000.00%
Last trade - 00:00- $326.59m
- $316.08m
Annual cashflow statement for Greenwich Lifesciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.57 | -7.83 | -8.89 | -15.8 | -19.4 |
| Amortisation | |||||
| Non-Cash Items | 0.661 | 1.74 | 2.38 | 7.25 | 6.8 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.385 | -0.122 | 0.032 | 1.27 | 2.64 |
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -4.29 | -6.2 | -6.48 | -7.27 | -9.91 |
| Financing Cash Flow Items | — | — | — | 4.37 | 11.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.84 | -7.54 | 0 | 4.37 | 12 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.46 | -13.7 | -6.48 | -2.9 | 2.09 |